Cloud-based AI Detection of Diabetic Retinopathy Stephen G. Odaibo, M.D., completed
his fellowship in Medical Retina at
2020 FIRST-YEAR RESIDENTS Anvesh Annadanam, M.D. B.S. – Biomedical engineering, Johns Hopkins University M.D. – Johns Hopkins University School of Medicine
Michigan Medicine in 2015, and credits his experience at the Kellogg Eye Center as a major influence in his career path and role as CEO and founder of RETINA-AI Health, Inc., an artificial intelligence company focused on retinabased detection of disease.
Dr. Odaibo recently led the company's Series A financing
campaign that raised $5.2M during a six-week period. The
Daniel Balikov, M.D., Ph.D. B.S.E. – Bioengineering, Biomedical Engineering, University of Pennsylvania Ph.D. – Biomedical Engineering, Vanderbilt University M.D. – Vanderbilt University School of Medicine
capital will be used to move the company’s cloud-based AI detector of diabetic retinopathy through FDA approval. The innovative technology, which takes a retinal image and returns a PDF report within a few seconds, is intended for use in the primary care setting.
Dr. Odaibo says his fellowship in Medical Retina at the
Kellogg Eye Center was instrumental in making him the type
Nikhil B.S. – M.D. –
Bommakanti, M.D. Bioengineering, Cell and Tissue Engineering, University of Illinois at Chicago Columbia University Vagelos College of Physicians
of retinal specialist he has become. Entering the match with advanced degrees in mathematics and computer science, he was looking for a fellowship where he could fully integrate his prior training and prepare for a multidisciplinary career. With Kellogg as his first fellowship choice, Dr. Odaibo says “There is a curiosity here about the full scope of eye disease — and this enabled me to hone my skill set toward innovation in
Otana Jakpor, M.D., M.Sc. B.S. – Global Health, Biological Sciences, University of Southern California M.Sc. – Epidemiology, London School of Hygiene and Tropical Medicine M.D. – Harvard Medical School
the retina space.”
Dr. Odaibo spends 90% of his professional time as CEO
of RETINA-AI Health, Inc., and 10% caring for patients. He is on the faculty at the MD Anderson Cancer Center and the University of Houston.
Omar Moinuddin, M.D. B.S. – Loyola University Chicago M.D. – Oakland University William Beaumont School of Medicine
“Kellogg offered the influence and training that I was look-
ing for — not just in terms of what was known, but also in terms of anticipating the future of healthcare delivery and preparing to help shape that future. The focus on academics and innovation at Kellogg played a critical role in my development.”
FIRST-YEAR POSTDOCTORAL FELLOW Molly Naylor earned her Ph.D. in Cellular and Molecular Biology from the University of Michigan through her study of plasma membrane repair in striated muscle. Molly is currently a Postdoctoral Fellow in Dr. Jillian Pearring’s laboratory, studying outer segment growth in photoreceptors. 32
David Skanchy, M.D. B.S. – Physiology and Developmental Biology, Brigham Young University M.D. – McGovern Medical School at The University of Texas - Houston
Jeffrey Yu, M.D. B.S. – Cell and Molecular Biology, Stanford University M.D. – University of California, Irvine, School of Medicine
